| 1. |
- Bergqvist, Michael, et al.
(författare)
-
Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer
- 2017
-
Ingår i: Acta Oncologica. - 0284-186X .- 1651-226X. ; 53:3, s. 441-447
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: The primary objective of this study was to compare the progression-free survival (PFS) at 12 weeks between patients treated with IGF-1R pathway modulator AXL1717 (AXL) and patients treated with docetaxel (DCT).MATERIAL AND METHODS: The study was conducted at 19 study centers in five countries. A total of 99 patients with previously treated, locally advanced or metastatic non-small cell lung cancer (NSCLC) of the squamous cell carcinoma (SCC) or adenocarcinoma (AC) subtypes in need of additional treatment were randomized and treated with either 300 or 400 mg of AXL as daily BID treatment (58 patients) or DCT given as 75 mg/m(2) in three-week cycles (41 patients) as monotherapy in a 3:2 ratio for each NSCLC subtype. Patients were treated in the primary study treatment period for a maximum of four treatment cycles.RESULTS: The 12-week PFS rate, median PFS and overall survival (OS), as well Kaplan-Meier hazard ratio for PFS and OS, did not show any statistically significant differences between the treatment groups. For the primary endpoint, the AXL group had a lower percentage of patients (25.9%) who were progression-free at Week 12 as compared to the DCT group (39.0%), although the difference was not statistically significant. The most notable difference in the incidence of treatment emergent adverse effects (TEAEs) was the lower incidence of treatment-related grade 3/4 neutropenia in patients treated with AXL.CONCLUSION: These results suggest neither of the treatments to be superior of the other when treating locally advanced or metastatic NSCLC. Considering the lower incidence of grade 3/4 neutropenia in the AXL group this treatment warrants further research.
|
|
| 2. |
- Fors Brandebo, Maria, 1979-, et al.
(författare)
-
Re-enlistment in the Swedish Armed Forces – individual motives and driving forces
- 2016
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- As many other armed forces, the Swedish Armed Forces (SAF) is having a difficult time recruiting a sufficient number of soldiers. The turn-over rate is high as well as the cost for recruiting and training soldiers, should they leave the SAF immediately (after basic training) or after a shorter period of employment. This has brought attention to the issue of re-enlistment and the need to understand what factors impact soldiers’ willingness to re-enlist to the SAF. The aim of the study is to investigate the motives and driving forces that make soldiers inclined to re-enlist within the SAF. Interviews are conducted with about 20 re-enlisted soldiers from three different units. A grounded-theory approach will be used to analyse the data. At the time of the conference the data analysis will be completed and the results will be presented.
|
|
| 3. |
- Fors Brandebo, Maria, et al.
(författare)
-
Återanställning i Försvarsmakten : en intervjustudie med återanställda soldater
- 2016
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- Syftet med studien var att undersöka motiven hos soldater som tagit återanställ-ning i Försvarsmakten. Följande frågeställningar belystes: (1) Vilka faktorer påverkade beslutet att lämna Försvarsmakten? och (2) Vilka faktorer påverkade beslutet att ta återanställning i Försvarsmakten? Elva soldater, från tre olika förband, som hade återanställts i Försvarsmakten intervjuades. Intervjuerna analyserades med en grounded theory-ansats. En teoretisk modell som beskriver återrekryteringsprocessen ur ett individperspektiv har tagits fram.Den teoretiska modellen visar att för att förstå återanställda soldaters motiv i samband med återanställning i Försvarsmakten behöver vi ta hänsyn till följande aspekter: (a) soldaternas inställning till sitt arbete, (b) deras upplevelse av arbetet, (c) deras motiv och tankar i samband med beslut om att avsluta sin anställning, (d) deras reflektionsprocess som uppstår i kontrasten med den civila kontexten, och (e) deras motiv och tankar i samband med beslutet att ta återanställning i Försvarsmakten. I rapporten diskuteras bland annat betydelsen av målbilder, befälens syn på återanställda soldater och engagemang och intresse för Försvarsmakten som ett resultat av reflektionsprocessen.
|
|
| 4. |
- Holgersson, Georg, et al.
(författare)
-
A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer
- 2015
-
Ingår i: Medical Oncology. - : Springer Science and Business Media LLC. - 1357-0560 .- 1559-131X. ; 32:4
-
Tidskriftsartikel (refereegranskat)abstract
- AXL1717 is an orally bioavailable IGF-1R pathway modulator that has been shown to have anti-tumoral effects. The objectives of the present study were to define maximum tolerated dose and the recommended phase II dose (RPTD) of AXL1717 in combination with gemcitabine HCl and carboplatin in non-small cell lung cancer (NSCLC). Patients with previously untreated, locally advanced, or metastatic NSCLC (squamous cell cancer or adenocarcinoma) in good performance status and with preserved major organ functions were enrolled in the study. The study was an open-label phase I study with planned cohorts of three patients per dose level of AXL1717 (215, 290, and 390 mg BID). In total, 12 patients were enrolled in the study, and of these, two were prematurely excluded. AXL1717 was administered at one dose level, 215 mg BID. A total number of 81 unique adverse events were reported. Bone marrow toxicity was reported in 10 out of 12 patients, and this organ class showed the largest number of related events. AXL1717 in combination with gemcitabine HCl and carboplatin is a possible treatment approach in previously untreated, locally advanced, or metastatic non-small cell lung cancer. However, due to the bone marrow toxicity profile shown in the present study, further dose increases of AXL1717 above 215 mg BID will probably not be feasible. Therefore, 215 mg BID constitutes maximum tolerated dose and RPTD.
|
|
